Trial Profile

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LOXO-338 (Primary) ; Pirtobrutinib (Primary)
Indications B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

03 Mar 2026 Planned End Date changed from 1 Dec 2025 to 1 Jun 2026.
18 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
28 May 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com